Given the central role of the inflammatory cascade in COVID-19 pathogenesis, there is growing interest in the potential use of tumour necrosis factor-alpha (TNF-α) inhibitors as a therapeutic strategy to mitigate this response and improve patient outcomes [4, 5]. The gene discussed is TNF; the disease is COVID-19.